Alexander Spira, MD, PhD, FACP, Discusses Impacts of COVID-19 at Individual Treatment Facilities

Video

CancerNetwork® sat down with Alexander Spira, MD, PhD, FACP, at the 2021 World Conference on Lung Cancer to talk about COVID-19 and immediate changes that took place during the pandemic.

At the 2021 World Conference on Lung Cancer, CancerNetwork® spoke with Alexander Spira, MD, PhD, FACP, of Virginia Cancer Specialists, about how COVID-19 drastically changed his institution and what has been implemented to keep providers and patients safe.

Transcript:

COVID-19 has really changed how we think and how we’ve done everything. We never closed [my institution], but we did a lot of telemedicine visits; we still are, but not as much as before. [COVID-19 has] affected everything from our research program to our patients. Most importantly, it’s affected the patients because we’ve limited visitors for obvious reasons. This has been a harder time for the patients and their loved ones to not have somebody with them when they’re in clinic getting their infusion. We’ve all at this point become accustomed to it. We’re all masked up, I’ve got mine sitting right next to me. It’s just been tough and challenging. We’ve all evolved [but] it’ll be great to get back to normal at some point, though.

Related Videos
Collaboration among nurses, social workers, and others may help in safely administering outpatient bispecific T-cell engager therapy to patients.
Nurses should be educated on cranial nerve impairment that may affect those with multiple myeloma who receive cilta-cel, says Leslie Bennett, MSN, RN.
Treatment with cilta-cel may give patients with multiple myeloma “more time,” according to Ishmael Applewhite, BSN, RN-BC, OCN.
Nurses may need to help patients with multiple myeloma adjust to walking differently in the event of peripheral neuropathy following cilta-cel.
Video 4 - "Frontline Treatment for EGFR-Mutated Lung Cancer"
Video 3 - "NGS Testing Challenges and Considerations in NSCLC"
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.